Advertisement
UK markets closed

  • NIKKEI 225

    37,628.48
    -831.60 (-2.16%)
     

  • HANG SENG

    17,284.54
    +83.27 (+0.48%)
     

  • CRUDE OIL

    83.77
    +0.96 (+1.16%)
     

  • GOLD FUTURES

    2,344.30
    +5.90 (+0.25%)
     

  • DOW

    38,085.80
    -375.12 (-0.98%)
     

  • Bitcoin GBP

    51,766.93
    +557.45 (+1.09%)
     

  • CMC Crypto 200

    1,397.22
    +14.65 (+1.06%)
     

  • NASDAQ Composite

    15,611.76
    -100.99 (-0.64%)
     

  • UK FTSE All Share

    4,387.94
    +13.88 (+0.32%)
     
Stocks:

Trending tickers

Microsoft, Alphabet, Anglo American, IBM, Astrazeneca, Unilever and Sainsbury's

BUZZ-European healthcare: safety check

Reuters - UK Focus

** The healthcare sector set to lose its lustre as M&A premium disappears and rich valuations diminish its attraction as a relatively less-risky sector.

** Among the best performers YTD across Europe, up almost 11 pct vs 3 pct drop on broad STOXX Europe 600.

** But valuations now pricey. Chart: http://link.reuters.com/syz23w

** Sector has become more volatile, beta higher than European banks: Chart: http://link.reuters.com/hyz23w

** Recent AbbVie u-turn on planned Shire inversion deal sent Shire (Xetra: S7E.DE - news) stock plummeting to levels seen when news of bid first broke in June.

** AstraZeneca (NYSE: AZN - news) , which had rebuffed a $118 bln takeover bid from U.S. drugmaker Pfizer (NYSE: PFE - news) , down 16 pct from May peak. (RM (LSE: RM.L - news) : tricia.wright1.thomsonreuters.com@reuters.net, vikram.subhedar.thomsonreuters.com@reuters.net)